These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 26600218)

  • 21. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
    J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of antiviral therapy in the management of hepatocellular carcinoma.
    Guan YS; He Q
    Anticancer Drugs; 2013 Apr; 24(4):337-43. PubMed ID: 23388161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease.
    Trinchet JC; Ganne-Carrié N; Nahon P; N'kontchou G; Beaugrand M
    World J Gastroenterol; 2007 May; 13(17):2455-60. PubMed ID: 17552029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
    Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
    Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What Comes First: Treatment of Viral Hepatitis or Liver Cancer?
    Feld JJ; Krassenburg LAP
    Dig Dis Sci; 2019 Apr; 64(4):1041-1049. PubMed ID: 30874985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma and hepatitis C in the United States.
    El-Serag HB
    Hepatology; 2002 Nov; 36(5 Suppl 1):S74-83. PubMed ID: 12407579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
    Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A; Nishiguchi S; Shiomi S; Hayashi T; Kobayashi S; Habu D; Takeda T; Seki S; Hirohashi K; Tanaka H; Kubo S
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
    Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K
    J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b.
    Nishise Y; Saito T; Sugahara K; Ito JI; Saito K; Togashi H; Nagano-Fujii M; Hotta H; Kawata S
    J Infect Dis; 2007 Oct; 196(7):1006-9. PubMed ID: 17763321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
    Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncologic Implications of Chronic Hepatitis C Virus Infection.
    Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
    J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.